HCPCS Code J2329: Injection, ublituximab-xiiy, 1mg

## **HCPCS code J2329 documentation requirements** ### **Code and units** When billing HCPCS code J2329, the code must be entered clearly, with the total number of units reported to reflect the exact milligrams administered. For example, if a patient receives 150 mg, the claim should indicate 150 units. ### **Diagnosis** The claim must include the correct diagnosis code that supports medical necessity for ublituximab-xiiy, typically a relapsing form of multiple sclerosis. The diagnosis should be linked directly to the service line for accurate claims processing. ### **NDC and drug details** Most payers require inclusion of the National Drug Code (NDC) along with the unit of measure qualifier and quantity. This information ensures the drug is properly identified and reimbursed at the correct rate. ### **Provider and service location** The rendering provider’s National Provider Identifier (NPI) must be reported, along with the service facility location where the infusion was administered. This ensures claims accurately reflect who performed the service and where it took place. ### **Prior authorization** Some payers require prior authorization before administering ublituximab-xiiy. If applicable, the authorization number should be included in the claim submission to prevent denials. ### **Discarded drug reporting** Medicare requires the use of modifiers for single-use vials. Use the JW modifier when a portion of the drug is discarded, and the JZ modifier when no drug is discarded. This ensures compliance with CMS waste-reporting policies. ### **Specialty pharmacy considerations** If the medication is supplied through a specialty pharmacy, additional billing for drug administration codes may be required. Providers should follow payer-specific instructions in these cases.

## **J2329 billing requirements** The billing requirements for HCPCS code J2329 (Injection, ublituximab-xiiy, 1mg) include: ### **Code and units** When billing HCPCS code J2329, report the exact number of units that reflect the total milligrams administered. Each milligram equals one unit. For example, a 150 mg infusion should be billed as 150 units. ### **Drug administration codes** Payers typically require that the drug and its administration be billed together as a single unit. Alongside J2329, include the appropriate CPT code for intravenous infusion or injection as directed by payer guidelines. ### **Modifiers** When applicable, modifiers must be used to accurately reflect drug waste. The JZ modifier is used to indicate that zero drug amount was discarded or not administered. The JW modifier is used when a portion of the single-use vial was discarded. ### **Payer-specific requirements** Each payer may have unique rules for billing J2329. Providers should follow instructions for claim submission, required documentation, and timelines to avoid delays or denials. ### **Specialty pharmacy considerations** If ublituximab-xiiy is supplied through a specialty pharmacy, confirm with the payer how the drug administration should be reported. Some plans require separate billing for the drug and the infusion service. ### **Claim submission** Claims can be submitted electronically or on paper. For paper claims, forms such as the CMS-1500 or UB-04 must be completed with the correct codes and provider details. Electronic claims must mirror these requirements through the appropriate reporting fields. ### **Medical decision-making** Billing for J2329 typically involves moderate complexity of medical decision-making, which must be reflected in the supporting documentation. This includes showing the rationale for treatment, monitoring, and risk management associated with multiple sclerosis care.

## **Other relevant codes** - **J3490**: Unclassified drugs - **J3590**: Unclassified biologics - **J9999**: Not otherwise classified, antineoplastic drugs - **C9399**: Unclassified drugs or biologicals